Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic cancer, adult 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Adenoma, Islet Cell 1

Interventions

Bevacizumab 37Oxaliplatin 17Capecitabine 17Irinotecan 15Leucovorin 13HMPL-013 12Fluorouracil 12Cetuximab 11trifluridine tipiracil drug combination 7irinotecan sucrosofate 6tipiracil 5Trifluridine 5Specimen Handling 5Drug Therapy 5tislelizumab 4Standard of Care 4Mitomycin 4Magnetic Resonance Spectroscopy 4Injections 4Folfox protocol 4trametinib 3toripalimab 3pembrolizumab 3Nivolumab 3IFL protocol 3Colonoscopy 3Blood Specimen Collection 3Biopsy 3sotorasib 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Neoplasms × nimotuzumab × Clear all
NCT06343116 2024-04-02

NOTABLE-308

Biotech Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡